Body weight cycling, also known as “yo-yo dieting,” is associated with a 25%-36% increased risk for diabetic kidney disease ...

The first clinical trials using organs from genetically modified pigs offer hope to patients with kidney failure, who face a ...

Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with ...

For the second time in less than a year, doctors at Massachusetts General Hospital have transplanted a genetically-edited pig ...

Older adults with advanced kidney disease are often motivated to receive a transplant but may face emotional and psychosocial ...

A year after guidelines were revised to remove the use of race in eGFR, many labs and pathologists were still relying on the ...

Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in ...

Chronic kidney disease is a common complication for people living with type 2 diabetes. Diabetes is the leading cause of ...

Kidney disease affects millions of Americans, with Black communities facing disproportionately higher risks due to genetic factors, socioeconomic challenges, ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...